After decades with no pharmaceutical option for the millions of Americans living with fatty liver disease, the FDA granted accelerated approval to Rezdiffra (resmetirom) on March 14, 2024 — making it the first-ever medication approved to treat nonalcoholic steatohepatitis, or NASH. Developed by Madrigal Pharmaceuticals, this oral, once-daily pill is approved for adults with noncirrhotic NASH with moderate to advanced liver fibrosis (stages F2 to F3), and it must be used alongside diet and exercise. For the estimated 6 to 8 million Americans who fall into that category, this approval represents a genuine turning point. Consider someone like a 58-year-old woman whose liver biopsy revealed stage F2 fibrosis three years ago — until now, her doctor could only recommend weight loss and dietary changes, with no drug to prescribe. That has finally changed. But approval is only part of the story.
Rezdiffra’s clinical data is promising, though not without caveats. It remains under accelerated approval, meaning full confirmation depends on ongoing trial results. The drug costs roughly $47,400 per year at wholesale, raising serious questions about access. And a second treatment option — semaglutide, better known as Wegovy — has since entered the picture for MASH patients. This article breaks down how Rezdiffra works, what the clinical trials actually showed, who qualifies, what it costs, what the side effects look like, and what the arrival of a second drug means for people managing this disease. The connection between liver disease and brain health is more relevant than many people realize. NASH-related inflammation and metabolic dysfunction have been linked to increased risk of cognitive decline, making this approval significant not just for hepatologists but for anyone tracking the metabolic drivers of dementia.
Table of Contents
- What Is the First Approved Drug for Non-Alcoholic Fatty Liver Disease, and How Does It Work?
- What the Clinical Trial Data Actually Shows — And Where It Falls Short
- The Liver-Brain Connection — Why a Fatty Liver Drug Matters for Dementia Risk
- What Does Rezdiffra Cost, and Can People Actually Afford It?
- Side Effects and Who Should Not Take Rezdiffra
- The Scale of the Problem — Why 86 Million Americans Should Pay Attention
- What Comes Next for Fatty Liver Disease Treatment
- Conclusion
- Frequently Asked Questions
What Is the First Approved Drug for Non-Alcoholic Fatty Liver Disease, and How Does It Work?
Rezdiffra works by activating the thyroid hormone receptor-beta (THR-β) in the liver. This receptor plays a central role in how the liver processes fat. When activated, it reduces fat accumulation in liver cells — the core driver behind the progression from simple fatty liver to the inflamed, scarred state known as NASH or MASH (the newer terminology, metabolic dysfunction-associated steatohepatitis). The drug is available in 60 mg, 80 mg, and 100 mg tablets and is taken once daily by mouth. What makes Rezdiffra different from supplements or off-label medications that have been tried over the years is that it was designed and tested specifically for this disease. Previous attempts to repurpose diabetes drugs, vitamin E, or other agents produced inconsistent results and never earned FDA approval for NASH.
Rezdiffra’s mechanism is targeted: rather than broadly affecting metabolism, it zeroes in on the liver’s fat-processing pathway through a specific receptor. The European Commission has also granted conditional marketing authorization, making Rezdiffra the first approved MASH therapy in the EU as well. It is worth noting what Rezdiffra is not approved for. It is not indicated for patients who have already progressed to cirrhosis (stage F4), nor is it a treatment for simple fatty liver without fibrosis. The approval is narrow by design — limited to that middle window of moderate to advanced fibrosis where intervention can potentially prevent the irreversible damage of end-stage liver disease. Patients with early-stage disease or those who have already reached cirrhosis are not currently candidates for this drug.
What the Clinical Trial Data Actually Shows — And Where It Falls Short
The pivotal MAESTRO-NASH Phase 3 trial enrolled 966 patients in its primary analysis, split roughly into thirds: 322 received 80 mg, 323 received 100 mg, and 321 received placebo. On the primary endpoint of NASH resolution without worsening fibrosis, 25.9% of those on the 80 mg dose and 29.9% on the 100 mg dose achieved resolution, compared to just 9.7% on placebo. For fibrosis improvement of at least one stage without worsening disease activity, the numbers were 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% on placebo. These numbers deserve honest context. Roughly one in four patients on the drug saw meaningful improvement — which is significant when compared to placebo, but it also means that three out of four patients on the higher dose did not achieve NASH resolution. This is not a cure.
It is a tool that, for a meaningful subset of patients, can slow or partially reverse liver damage. The fibrosis improvement numbers tell a similar story: better than placebo by about 10 to 12 percentage points, but far from a guarantee. However, if you are someone whose liver biopsy shows stage F2 or F3 fibrosis and whose condition has been worsening despite lifestyle changes, even a 25 to 30% chance of resolution is medically meaningful — especially when the alternative was no treatment at all. The drug also remains under accelerated approval, which means the FDA granted it based on surrogate endpoints (biopsy improvements) rather than long-term outcomes like reduced liver failure or death. The MAESTRO-NASH OUTCOMES trial, now fully enrolled, is evaluating whether Rezdiffra reduces liver decompensation events in patients with compensated NASH cirrhosis. Those results will determine whether the drug earns full approval.
The Liver-Brain Connection — Why a Fatty Liver Drug Matters for Dementia Risk
The relationship between metabolic liver disease and cognitive decline is an area of growing research interest, and it adds an important dimension to why this drug approval matters beyond gastroenterology. MASLD — the umbrella term for fatty liver disease — affects approximately 33.7% of U.S. adults, roughly 86 million people. that overlaps substantially with the population at risk for metabolic syndrome, type 2 diabetes, and cardiovascular disease, all of which are established risk factors for Alzheimer’s disease and vascular dementia. Chronic liver inflammation drives systemic inflammation, elevated insulin resistance, and disrupted lipid metabolism — each of which can damage the blood-brain barrier and accelerate neurodegenerative processes.
Several epidemiological studies have found that patients with NAFLD have higher rates of cognitive impairment compared to age-matched controls. A 62-year-old man with stage F3 fibrosis is not only at risk for liver failure; he is also carrying a metabolic burden that may be quietly affecting his brain. Treating the liver disease may, in theory, reduce one tributary feeding into that broader metabolic storm. This does not mean Rezdiffra is a dementia drug, and no one should take it for cognitive reasons. But for families already navigating a dementia diagnosis or managing brain health proactively, understanding that fatty liver disease is part of the same metabolic picture — and that there is now a treatment for it — matters. Addressing liver health is increasingly being recognized as part of a comprehensive approach to protecting the aging brain.
What Does Rezdiffra Cost, and Can People Actually Afford It?
The wholesale acquisition cost for Rezdiffra is approximately $47,400 per year. At the retail level, a 30-tablet supply runs about $4,149. The Institute for Clinical and Economic Review (ICER) estimated a cost-effectiveness range of $39,600 to $50,100 per year, suggesting the current pricing falls within — though at the high end of — what might be considered proportional to the drug’s clinical benefit. For commercially insured patients, Madrigal Pharmaceuticals offers a copay assistance card that can reduce out-of-pocket costs to as little as $0. Patients without commercial coverage may qualify for programs that bring the cost down to approximately $10 per month.
These programs are common in the specialty drug market, though they do not help everyone — patients on Medicare Part D, for example, are typically ineligible for manufacturer copay cards, and those individuals may face significant cost burdens. The tradeoff is stark: a drug that finally exists for a disease that affects millions, but at a price that without assistance is out of reach for most of them. By comparison, semaglutide (Wegovy), which has also received FDA approval for MASH with moderate to advanced fibrosis, operates through a completely different mechanism — it is a GLP-1 receptor agonist, the same class as the widely prescribed weight-loss and diabetes drugs. For patients who are already taking semaglutide for weight management or type 2 diabetes, the overlap could simplify treatment. For others, the choice between Rezdiffra and semaglutide will depend on insurance coverage, tolerability, existing medications, and physician preference. Having two approved options is a meaningful improvement, but it also introduces complexity into treatment decisions that did not exist two years ago.
Side Effects and Who Should Not Take Rezdiffra
The most common side effects reported in clinical trials, occurring in 5% or more of participants, were diarrhea, nausea, pruritus (itching), vomiting, constipation, abdominal pain, and dizziness. The gastrointestinal side effects are not surprising given the drug’s mechanism — altering fat metabolism in the liver has downstream effects on digestion. For most patients in the trials, these were manageable, but for someone already dealing with gastrointestinal issues from other medications or conditions, the added burden could be a reason to reconsider. A limitation that is easy to overlook: Rezdiffra is not a standalone treatment. The FDA approval explicitly requires that it be used in conjunction with diet and exercise.
This is not a drug that allows patients to continue the dietary patterns that contributed to their liver disease. In practice, this means a patient who cannot or will not make lifestyle modifications may see reduced benefit, and prescribers should be having frank conversations about this requirement rather than treating the prescription as a complete solution. Patients with decompensated cirrhosis, severe liver impairment, or certain thyroid conditions should discuss risks carefully with their physicians. Because the drug is still under accelerated approval, there is an inherent uncertainty about its long-term safety profile. The confirmatory outcomes trial will provide more data, but for now, patients and clinicians are making decisions based on a promising but incomplete picture. Anyone considering Rezdiffra should have a current liver biopsy confirming their fibrosis stage and a thorough conversation with a hepatologist — not just a primary care provider — about whether the drug is appropriate for their specific situation.
The Scale of the Problem — Why 86 Million Americans Should Pay Attention
The numbers behind fatty liver disease are staggering and still not widely understood by the public. MASLD affects approximately 33.7% of U.S. adults — around 86 million people. Of those, an estimated 15 million have progressed to MASH, the inflammatory stage. And MASH prevalence is projected to increase by 63% by 2030, driven by rising rates of obesity, type 2 diabetes, and metabolic syndrome.
A disease that was barely discussed in mainstream medicine 20 years ago is now one of the most common chronic liver conditions in the country. For context, consider that before March 2024, every one of those millions of patients had exactly zero FDA-approved pharmaceutical options. A physician diagnosing stage F2 fibrosis could recommend weight loss, dietary changes, and exercise — all of which are effective when sustained, but which most patients struggle to maintain long-term. The approval of Rezdiffra, followed by semaglutide’s indication for MASH, does not erase the importance of lifestyle intervention. But it does mean that the medical toolkit is no longer empty.
What Comes Next for Fatty Liver Disease Treatment
The treatment landscape for MASH is evolving rapidly. Rezdiffra remains under accelerated approval as of March 2026, with the MAESTRO-NASH OUTCOMES trial expected to provide the data needed for full FDA approval. The addition of semaglutide as a second approved option has introduced both competition and complementary treatment possibilities — some researchers are already exploring whether combining a THR-β agonist like Rezdiffra with a GLP-1 drug could produce better outcomes than either alone.
Beyond these two drugs, the pipeline includes several other mechanisms of action under investigation. The fact that the FDA has now approved treatments for MASH has opened the door for pharmaceutical investment in a space that was largely ignored for years. For patients and caregivers focused on brain health, the broader takeaway is this: metabolic health and neurological health are deeply intertwined, and advances in treating conditions like fatty liver disease may ultimately contribute to reducing dementia risk at the population level. This is not speculation — it is the direction that metabolic neuroscience is heading.
Conclusion
The approval of Rezdiffra marked the end of a long and frustrating era in which tens of millions of Americans with fatty liver disease had no drug to turn to. The clinical trial data shows meaningful, if modest, improvement in NASH resolution and fibrosis — roughly one in four patients benefiting at the higher dose. The arrival of semaglutide as a second option adds flexibility, and ongoing trials will determine whether these drugs can prevent the hard outcomes that matter most: liver failure, transplant, and death. The cost remains a real barrier for many, though assistance programs exist for those who qualify.
For readers of this site, the relevance extends beyond the liver. Metabolic dysfunction-associated liver disease shares root causes with the vascular and inflammatory processes that drive cognitive decline. Managing fatty liver disease — through lifestyle changes, and now through medication when appropriate — is part of a broader strategy for protecting the aging brain. If you or a family member has been diagnosed with NASH or MASH, this is a conversation worth having with a hepatologist sooner rather than later.
Frequently Asked Questions
What is Rezdiffra, and what does it treat?
Rezdiffra (resmetirom) is the first FDA-approved drug for nonalcoholic steatohepatitis (NASH), now called MASH. It is approved for adults with noncirrhotic NASH with moderate to advanced liver fibrosis (stages F2 to F3) and must be used with diet and exercise.
How much does Rezdiffra cost without insurance?
The wholesale acquisition cost is approximately $47,400 per year, with a retail price of about $4,149 for 30 tablets. Commercially insured patients may pay as little as $0 with a copay card, and some uninsured patients may qualify for programs offering the drug at approximately $10 per month.
What are the most common side effects of Rezdiffra?
The most frequently reported side effects include diarrhea, nausea, pruritus (itching), vomiting, constipation, abdominal pain, and dizziness.
Is Rezdiffra fully FDA approved?
No. As of March 2026, Rezdiffra remains under accelerated approval. Full approval depends on the results of the MAESTRO-NASH OUTCOMES confirmatory trial, which is evaluating whether the drug reduces serious liver events in patients with compensated NASH cirrhosis.
Is there a connection between fatty liver disease and dementia?
Research increasingly links MASLD and MASH with elevated risk of cognitive decline. The shared metabolic drivers — insulin resistance, chronic inflammation, and disrupted lipid metabolism — can affect both liver and brain health. Treating liver disease may be one component of a broader strategy for reducing dementia risk.
Are there other drugs approved for fatty liver disease besides Rezdiffra?
Yes. Semaglutide (Wegovy), a GLP-1 receptor agonist, has also received FDA approval for MASH with moderate to advanced fibrosis, providing a second treatment option with a different mechanism of action.
